Patents Assigned to Modex Therapeutiques, S.A.
  • Patent number: 6673603
    Abstract: The present invention provides the use and composition of matter of angiogenic or other growth factors expressed by combining various types and stages of differentiation of allogeneic human cell strains or lines in unencapsulated pastes (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) to be temporarily applied to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: January 6, 2004
    Assignee: Modex Therapeutiques, S.A.
    Inventors: E. Edward Baetge, Thomas Hunziker, Alain Limat, Vincent Ronfard
  • Patent number: 6451601
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: September 17, 2002
    Assignee: Modex Therapeutiques, S.A.
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Patent number: 6358739
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Modex Therapeutiques, S.A.
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens